Literature DB >> 26676809

The association between serious infection and disease outcome in patients with rheumatoid arthritis.

Mikiko Iguchi-Hashimoto1, Motomu Hashimoto2, Takao Fujii3, Masahide Hamaguchi4, Moritoshi Furu3, Masahiro Ishikawa3, Hiromu Ito3,5, Noriyuki Yamakawa1, Chikashi Terao6, Keiichi Yamamoto7, Wataru Yamamoto1,8, Koichiro Ohmura1, Tsuneyo Mimori1.   

Abstract

The purpose of this study was to study the association between the past history of serious infection (SI) that required hospitalization and the current disease status of rheumatoid arthritis (RA), including disease activity, physical disability, and radiological joint destruction. The history of hospitalized infection was retrospectively analyzed in a cohort of 370 RA patients. The patients were divided into three groups based on the number of SI events (SI = 0, SI = 1, SI ≥ 2). Disease activity score using 28 joints (DAS28), Health Assessment Questionnaire (HAQ), and modified total sharp score (mTSS) adjusted after disease duration or other confounding factors were compared among the three groups. Among the study patients, 7.3% (27 patients) experienced single SI (SI = 1) and 2.1% (8 patients) experienced multiple SI events (SI ≥ 2). Compared with patients with no SI (SI = 0), patients with SI (SI = 1 or SI ≥ 2) had increased pulmonary and autoimmune comorbidities and were more frequently treated with glucocorticoids. DAS28 was not different among the groups, while HAQ and mTSS increased with the number of SI. After adjustment, only mTSS adjusted after disease duration remained statistically significantly different between patients with SI = 0 and SI ≥ 2 (p = 0.030). Multiple SI events are associated with advanced physical disability and radiological joint destruction in patients with RA.

Entities:  

Keywords:  Biological disease modifying anti-rheumatic drugs; Comorbidities; Glucocorticoids; Rheumatoid arthritis; Serious infection

Mesh:

Substances:

Year:  2015        PMID: 26676809     DOI: 10.1007/s10067-015-3143-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  25 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

3.  Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.

Authors:  Tim Bongartz; Carlotta Nannini; Yimy F Medina-Velasquez; Sara J Achenbach; Cynthia S Crowson; Jay H Ryu; Robert Vassallo; Sherine E Gabriel; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2010-06

4.  The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.

Authors:  Jeffrey R Curtis; Fenglong Xie; Lang Chen; John W Baddley; Timothy Beukelman; Kenneth G Saag; Claire Spettell; Raechele M McMahan; Joaquim Fernandes; Kevin Winthrop; Elizabeth Delzell
Journal:  Ann Rheum Dis       Date:  2011-05-17       Impact factor: 19.103

5.  Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years.

Authors:  C Turesson; W M O'Fallon; C S Crowson; S E Gabriel; E L Matteson
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

6.  Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission.

Authors:  Esmeralda T H Molenaar; Alexandre E Voskuyl; Huib J Dinant; P Dick Bezemer; Maarten Boers; Ben A C Dijkmans
Journal:  Arthritis Rheum       Date:  2004-01

7.  Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis.

Authors:  Jessica Widdifield; Sasha Bernatsky; J Michael Paterson; Nadia Gunraj; J Carter Thorne; Janet Pope; Alfred Cividino; Claire Bombardier
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-03       Impact factor: 4.794

8.  Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.

Authors:  Fabiola Atzeni; Piercarlo Sarzi-Puttini; Costantino Botsios; Antonio Carletto; Paola Cipriani; Ennio Giulio Favalli; Elena Frati; Valentina Foschi; Stefania Gasparini; AnnaRita Giardina; Elisa Gremese; Florenzo Iannone; Marco Sebastiani; Tamara Ziglioli; Domenico Biasi; Clodoveo Ferri; Mauro Galeazzi; Roberto Gerli; Roberto Giacomelli; Roberto Gorla; Marcello Govoni; Giovanni Lapadula; Antonio Marchesoni; Fausto Salaffi; Leonardo Punzi; Giovanni Triolo; Gianfranco Ferraccioli
Journal:  Autoimmun Rev       Date:  2012-07-13       Impact factor: 9.754

9.  Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis.

Authors:  D van der Heijde; L Klareskog; R Landewé; G A W Bruyn; A Cantagrel; P Durez; G Herrero-Beaumont; Y Molad; C Codreanu; G Valentini; R Zahora; R Pedersen; D MacPeek; J Wajdula; S Fatenejad
Journal:  Arthritis Rheum       Date:  2007-12

10.  Three groups in the 28 joints for rheumatoid arthritis synovitis--analysis using more than 17,000 assessments in the KURAMA database.

Authors:  Chikashi Terao; Motomu Hashimoto; Keiichi Yamamoto; Kosaku Murakami; Koichiro Ohmura; Ran Nakashima; Noriyuki Yamakawa; Hajime Yoshifuji; Naoichiro Yukawa; Daisuke Kawabata; Takashi Usui; Hiroyuki Yoshitomi; Moritoshi Furu; Ryo Yamada; Fumihiko Matsuda; Hiromu Ito; Takao Fujii; Tsuneyo Mimori
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

View more
  2 in total

1.  Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study.

Authors:  Bella Mehta; Sofia Pedro; Gulsen Ozen; Andre Kalil; Frederick Wolfe; Ted Mikuls; Kaleb Michaud
Journal:  RMD Open       Date:  2019-06-09

2.  Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis.

Authors:  Shunsaku Nakagawa; Mayumi Nakaishi; Motomu Hashimoto; Hiromu Ito; Wataru Yamamoto; Ran Nakashima; Masao Tanaka; Takao Fujii; Tomohiro Omura; Satoshi Imai; Takayuki Nakagawa; Atsushi Yonezawa; Hirohisa Imai; Tsuneyo Mimori; Kazuo Matsubara
Journal:  PLoS One       Date:  2018-11-02       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.